## **ICMJE DISCLOSURE FORM**

υaι	te:2022/7/2	.0	
	ur Name: Carlot		
			e treatment of metastatic colorectal cancer patients with
	esectable liver metastases _		·
	nuscript number (if known):		
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
rela par to t rela	ated to the content of your nation whose interests may be transparency and does not not not on the transparency are does not not on the transparency activity/interest, it	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	
The	tollowing questions apply t	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
<u>ma</u>	nuscript only.		
me In i	dication, even if that medica	ntion is not mentioned in to	all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other item
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All accompant fourths proposed	X None	ar planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	X_None			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	X None			
	Stock of Stock options	XNone			
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
	None				
- 1					

Please place an "X" next to the following statement to indicate your agreement:

 $\underline{X}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## **ICMJE DISCLOSURE FORM**

υaτ	e:2022///2	<u></u>	
You	r Name: Gugli	elmo Vetere	
			treatment of metastatic colorectal cancer patients with
	esectable liver metastases _		·
	- nuscript number (if known):		
rela par to t rela	ited to the content of your r ties whose interests may be ransparency and does not n itionship/activity/interest, i	manuscript. "Related" mea affected by the content o ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.  ps/activities/interests as they relate to the current
		o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
maı	nuscript only.		
med In it	dication, even if that medica	ntion is not mentioned in to	all relationships with manufacturers of antihypertensive he manuscript.  d in this manuscript without time limit. For all other item
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone	
	processing charges, etc.)		
	No time limit for this item.		
	time in this item.		
_		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	X None	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	X_None			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	X None			
	Stock of Stock options	XNone			
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
	None				
- 1					

Please place an "X" next to the following statement to indicate your agreement:

 $\underline{X}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## **ICMJE DISCLOSURE FORM**

vai	.e:2022/7/2	<u></u>	
Υοι	ır Name: Chiara	a Cremolini	
Ma	nuscript Title: FOLFOXII	RI plus bevacizumab in the	treatment of metastatic colorectal cancer patients with
	esectable liver metastases _		·
	nuscript number (if known):		
	,		
relaced to the test of the tes	ated to the content of your naties whose interests may be transparency and does not notionship/activity/interest, it following questions apply the nuscript only.	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship wities/interests should be only	os/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	tem #1 below, report all sup time frame for disclosure is	the past 36 months.	in this manuscript without time limit. For all other item
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	I planning of the work
	All support for the present	X None	
_	manuscript (e.g., funding,	XNone	
	provision of study materials,		
	1 .		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	t 36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
			I I
•	<u>'</u>	V No.	
3	Royalties or licenses	XNone	
3	<u>'</u>	XNone	
3 4	<u>'</u>	XNone XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	X_None			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	X None			
	Stock of Stock options	XNone			
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
	None				
- 1					

Please place an "X" next to the following statement to indicate your agreement:

 $\underline{X}$  I certify that I have answered every question and have not altered the wording of any of the questions on this form.